Pandion emerged with former Pfizer and Biogen execs; Hikma tapped ex-Fresenius scientist as CSO; Ipsen hired ex-Amgen oncology exec.
Marshall has served as Sosei CSO since it bought Heptares but is now departing to take on a senior role at another business.
The impact of protracted contracting timelines can be felt throughout the study start-up process. Coupling predictive enrollment analytics with contract…
European researchers discovered how drugs bind to the enzyme DHODH, which could lead to more selective cancer drugs.
John Hohneker will join Anokion Therapeutics as president and CEO from Forma Therapeutics, where he served as R&D chief.
Gilead and its $12 billion biotech buy Kite Pharma have teamed up with Pfizer to work on a Yescarta-utomilumab combo test in certain blood cancers.
In this week's EuroBiotech Report, Merck KGaA pens cancer pact, MDC details U.K. drug discovery goals and more.
In our EuroBiotech roundup this week, TxCell gets funding for CAR-Treg program, ETX strikes AI deals and Transgene advances hepatitis B program.
Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
The MDC identified efforts to make informatics tools, preclinical models, data and samples available to startups as the best uses of its resources.